Literature DB >> 20829050

Human glioma demonstrates cell line specific results with ATP-based chemiluminescent cellular proliferation assays.

Michael E Sughrue1, Martin J Rutkowski, Ari J Kane, Andrew T Parsa.   

Abstract

Alteration of tumor cell growth kinetics is the goal of nearly all current or proposed therapies for human neoplasms. The adenosine triphosphate (ATP) chemiluminescent assay has been used for some time as a surrogate marker of in vitro cell growth. Here we present data showing that three human glioblastoma cell lines (U87, U251, G55) demonstrate significantly different cell number to luminescence relationships when subjected to this assay. We plated progressively increasing numbers of cells per well; from 1000 to 50,000 were grown in Dulbecco's modified Eagle's medium without serum and cultured for 6 hours. Cells were then lysed and subjected to the chemiluminescent assay to measure ATP levels and a linear relationship between cell number and measured luminescence was found. Despite this, we found that the slope of the regression line (β) varied markedly between different cell lines (U251 [β = 0.968 ± 0.3] vs. U87 [β = 0.772 ± 0.2] vs. G55 [β = 0.757 ± 0.2]; p < 0.0001), suggesting a difference in ATP luminescence per cell between these cell lines. Thus, we have demonstrated that luminescence values are internally linear within a given cell population, but luminescence level per cell varies significantly between different glioma cell lines. Our findings suggest that different glioma cell lines have unique levels of ATP per cell.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829050      PMCID: PMC3795511          DOI: 10.1016/j.jocn.2010.05.007

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  22 in total

1.  The involvement of cellular ATP in receptor-mediated internalization of epidermal growth factor and hormone-induced internalization of beta-adrenergic receptors.

Authors:  C Hertel; S J Coulter; J P Perkins
Journal:  J Biol Chem       Date:  1986-05-05       Impact factor: 5.157

2.  ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects.

Authors:  H S Garewal; F R Ahmann; R B Schifman; A Celniker
Journal:  J Natl Cancer Inst       Date:  1986-11       Impact factor: 13.506

Review 3.  Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy.

Authors:  L Oliver; C Olivier; F B Marhuenda; M Campone; F M Vallette
Journal:  Curr Mol Pharmacol       Date:  2009-11       Impact factor: 3.339

4.  The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability.

Authors:  Y Maehara; H Anai; R Tamada; K Sugimachi
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

5.  Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).

Authors:  Pauline A Whitehouse; Louise A Knight; Federica Di Nicolantonio; Stuart J Mercer; Sanjay Sharma; Ian A Cree
Journal:  Anticancer Drugs       Date:  2003-06       Impact factor: 2.248

6.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.

Authors:  L Kangas; M Grönroos; A L Nieminen
Journal:  Med Biol       Date:  1984

7.  Quantitative and continuous analysis of ATP release from blood platelets with firefly luciferase luminescence.

Authors:  T Higashi; A Isomoto; I Tyuma; E Kakishita; M Uomoto; K Nagai
Journal:  Thromb Haemost       Date:  1985-02-18       Impact factor: 5.249

8.  [Comparison between the succinate dehydrogenase inhibition test and ATP assay for in vitro chemosensitivity testing].

Authors:  Y Maehara; K Miyamoto; H Anai; H Kusumoto; K Fukuchi; H Masuda; K Sugimachi
Journal:  Gan To Kagaku Ryoho       Date:  1987-03

9.  Comparison between succinate dehydrogenase inhibition test and subrenal capsule assay for chemosensitivity testing.

Authors:  H Anai; Y Maehara; H Kusumoto; K Sugimachi
Journal:  Oncology       Date:  1987       Impact factor: 2.935

10.  Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.

Authors:  Sanjay Sharma; Michael H Neale; Federica Di Nicolantonio; Louise A Knight; Pauline A Whitehouse; Stuart J Mercer; Bernard R Higgins; Alan Lamont; Richard Osborne; Andrew C Hindley; Christian M Kurbacher; Ian A Cree
Journal:  BMC Cancer       Date:  2003-07-03       Impact factor: 4.430

View more
  3 in total

1.  Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma.

Authors:  Martin J Rutkowski; Michael E Sughrue; Ari J Kane; Joseph M Kim; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2011-04-19       Impact factor: 4.130

2.  EMR-3: a potential mediator of invasive phenotypic variation in glioblastoma and novel therapeutic target.

Authors:  Ari J Kane; Michael E Sughrue; Martin J Rutkowski; Joanna J Phillips; Andrew T Parsa
Journal:  Neuroreport       Date:  2010-11-17       Impact factor: 1.837

3.  AG488 as a therapy against gliomas.

Authors:  Jadith Ziegler; Anja Bastian; Megan Lerner; Lora Bailey-Downs; Debra Saunders; Nataliya Smith; Jake Sutton; James D Battiste; Michael A Ihnat; Aleem Gangjee; Rheal A Towner
Journal:  Oncotarget       Date:  2017-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.